The treatment lead to increased infiltration of tumour tissues with immune cells suggesting involvement of ADCC. with immune cells suggesting involvement of ADCC. We found that SWA11 mAb treatment strongly altered the intratumoural cytokine microenvironment. The addition of SWA11 mAb to gemcitabine treatment strongly potentiated its anti-cancer efficacy in A549 lung cancer model. Conclusion: Our Istaroxime data demonstrate that targeting of CD24 could be beneficial for the anti-cancer treatment combined with standard chemotherapy regimes. Keywords: antibody, CD24, cancer stem cells Monoclonal antibodies have emerged as a new and important pillar for cancer therapy (Galluzzi was accompanied by changes in Src phosphorylation and the expression of STAT3-dependent genes (Bretz 4- to 5-week-old female SCID beige mice were purchased from Charles River Laboratories (Wetzlar, Istaroxime Germany) and housed at the animal facility of the German Cancer Research Center (Heidelberg, Germany). A549 human lung carcinoma cells (5 106 in 100?SWA11 treatment experiments with A549 human lung cancer model were performed and data from one representative experiment are shown. In one of these experiments, combined treatment with gemcitabine was investigated. this model was described in detail elsewhere (Wolterink mice (Charles River Laboratories) were inoculated with 5 106 human SKOV3ip ovarian cancer cells transfected with the luciferase plasmid pcDNA3.1 into the peritoneal cavity. Four days later, tumour-bearing animals were randomized and mice received either two injections of SWA11 mAb per week for 4 weeks (10?mg?kg?1 of mouse body weight), L1-9.3 or unspecific IgG2A or PBS vehicle. At the endpoint, mice were killed, weighed and the peritoneal cavity was thoroughly KPSH1 antibody examined for the formed tumour nodules. SKOV3ip tumours were excised, weighed and stored at ?80?C for further analysis. Two independent SWA11 mAb treatment experiments with SKOV3ip ovarian cancer model were performed and data from one representative experiment are shown. Animals bearing established A549 tumours first received an injection of SWA11 mAb (10?mg?kg?1) followed by administration of gemcitabine at a dose of 12?mg?kg?1 (10% of maximum tolerated dose for SCID mice) 1 day later. Treatment was repeated three times having a 5-day time interval. Animal experiments were authorized by the Baden-Wrttemberg animal oversight committee (Regierungspr?sidium Karlsruhe, Germany). Immunohistochemistry and immunofluorescence Immunohistochemistry was performed on 6?apoptosis detection kit (R&D Systems) according to the manufacturer’s recommendations and modified by transmission enhancement using a Vectastain ABC Elite kit (Vector Laboratories) and colour development using a DAB kit (Invitrogen). TUNEL-positive cells were counted at 400 magnification in 10 random fields of vision (0.089?mm2) per slip (washed once with ice-cold PBS and fixed with 4% PFA for 20?min on snow. For each time point duplicates were prepared. Fixed cells were washed twice with PBS and incubated with an anti-Alexa-488 antibody (25?and IL-1Ra. ELISA analysis showed a inclination to the improved protein levels of CCL5/RANTES, CXCL9/MIG and CCL2/MCP-1 after SWA11 mAb treatment (Number 4B). These results suggest that SWA11 mAb treatment induced severe changes in the tumour microenvironment that may have contributed to the restorative effect. Open in a separate window Number 3 Effects of SWA11 mAb treatment on intratumoural cytokine milieu in A549 tumours. (A) The levels of 40 different cytokines were identified in tumour lysates using a cytokine protein arrays. The level of cytokines was quantified using ImageJ software. Representative arrays from two self-employed SWA11 mAb treatment experiments Istaroxime are demonstrated. (B) Protein levels of CCL5/RANTES, CXCL9/MIG and CCL2/MCP-1 in tumour lysates ( Next, we investigated whether antibody focusing on of CD24 increases the anti-tumour effectiveness of chemotherapy. We tested whether pretreatment with SWA11 mAb would potentiate the effects of gemcitabine. In A549 tumour model, mice with founded xenograft tumours 1st received an injection of SWA11 mAb (10?mg?kg?1) followed by administration of gemcitabine at a dose of 12?mg?kg?1 (10% of maximum tolerated dose) 1 day later. Treatment was repeated.